Risk Partners Life Sciences Roundtable 2025, thank you very much! 

Contact us

We congratulate Formycon AG on its successful uplisting to the Prime Standard of Deutsche Börse on November 12, 2024!

Welcome to the Prime Standard league: A new champion of life sciences and biosimilars has successfully made the step from the scale segment. We proudly congratulate Enno Spillner, Dr. Caroline Redeker, Daniel Marquard and the entire Formycon AG team on this great success and another important milestone on their way to becoming a global champion in the biosimilars sector!

Formycon AG specializes in the development of high-quality biosimilars, which represent a cost-effective alternative to original biopharmaceutical preparations. The company demonstrates its innovative strength particularly in the field of follow-on molecules and has successfully positioned itself as one of the leading suppliers of biosimilars. With its expertise in research and development, Formycon creates access to cutting-edge biopharmaceutical products that benefit patients worldwide and has now also attracted increasing interest from international investors. As a result, the company has now been listed in the Prime Standard.  

Risk Partners acted as Capital Markets Insurance Advisor in this transaction. Our team, consisting of Florian, Franziska and Björn, supported Formycon AG during the successful uplisting process from the Scale to the Prime Standard of the Frankfurt Stock Exchange on November 12, 2024.

We are particularly pleased to contribute our specialization and expertise as an insurance broker for life sciences and capital market transactions and to accompany a "neighbor" from the Planegg/Martinsried region.

Special thanks also go to our co-broker team at Dr. Ellwanger & Kramm GmbH & Co. KG, in particular Gregor Klingeler and Frieder Lang, for the trust they have placed in us and the great cooperation. If you have a similar project in mind and would appreciate our support, please do not hesitate to contact us about the added value of RP4brokers. 

Also read our other blog posts
Being Public

"I believe in a strong IPO comeback in 2024" - Interview Platform Life Sciences

Risk Partners in the trade press. Florian was approached by the journalists from Plattform Life Sciences for an interview on our view of 2024 and the development of Risk Partners over the past year. In addition to challenging claims, product innovations (e.g. all about POSI insurance) from Risk Partners, Florian also discusses our motives for the "team up" with the fantastic colleagues from Atrialis GmbH - experts in clinical trials. Click here for Florian's interview. Read the interview

Read more "
January 11, 2024
Management

Capital requirements for (fully regulated) AIFMs

What are the capital requirements for an asset management company? Together with experts Johannes Kiefer (Director of Risk & Compliance at Landsiedel & Partner) and Henry Franz (Managing Director of Layline.tax), we were able to compile our combined expertise on capital requirements, ranging from registered asset management companies to fully licensed ones. In this issue of VC Magazine, we share how E&O insurance, among other things, can provide added value. In addition to our article available below, please also check out the link to the online edition of Venture Capital Magazine. Enjoy!

Read more "
March 30, 2026
Being Public

Digital and effective prevention of directors' and officers' liability by Risk Partners & Fides Technology

Innovation by Risk Partners & Fides Technology Now on Vimeo and Soundcloud: get practical tips from experts with high relevance for avoiding liability for business managers. Question unanswered? Content: Personal liability is a constant sword of Damocles hovering over managing directors in everyday life. The standard of care is strict and directors bear the burden of proof. In collaboration with the distinguished corporate lawyer Eva Homborg (Esche Schümann Commichau) and the governance expert Philippa Peters (Fides Technology GmbH), we have spent months compiling practical measures on how you can avoid this burden of proof.

Read more "
January 12, 2024
Management

Research breakdown at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research

Research mishap at Stockholm's Karolinska Institute: A cooling failure destroys cell cultures from decades of research - can you insure against it? An incident that threatens your very existence, but which we would like to shed some light on from the perspective of an insurance broker specializing in life sciences. What happened? A cooling system at the Karolinska Institute in Stockholm, Sweden's most important medical research center, failed for five days. Biological material that had been collected over 30 years and, according to the institute, was unique in the world, was destroyed as a result. The material was stored in deep-freeze tanks in which the temperature

Read more "
June 7, 2024
Being Public

Public prosecutor's office investigates: Suspicion of deception in short-time work (Sono Motors)

No startup bonus for criminal and administrative offenses. The incident and possible insurance cover. As exclusively researched by Hannah Schwär and her team at Capital Magazin, the founders of Sono Motors are now also facing problems with the public prosecutor's office. According to Capital Magazin, subsidy fraud in the context of short-time work and the programs surrounding the corona crisis is in the offing. The company, which is listed on the NASDAQ via De-SPAC, has already filed a report with the SEC. While the loss amount of EUR 40,000 is still being

Read more "
March 19, 2024
Life Sciences

St. Gallen study: USD 6 billion per drug

HSG St. Gallen: Drug costs USD 6.16 billion on average. Are the days of new drugs costing less than USD 1 billion over? There were figures in the industry that spoke of USD 700-1,000 million as the cost of developing a new drug. A study by the University of St. Gallen covering the period 2001-2020 found that the cost of developing new drugs has risen dramatically. It was estimated that the cost of developing a new drug now stands at

Read more "
September 26, 2023